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Patients Aged$60 Years with Hematologic Neoplasias
Treated with Allogeneic Hematopoietic Cell
Transplantation
Barbara Deschler,1 Kristin Binek,1 Gabriele Ihorst,2 Reinhard Marks,1 Ralph Wa¨sch,1
Hartmut Bertz,1 Ju¨rgen Finke1Toxicity-reduced conditioning is a curative treatment option for medically compromised or elderly patients
ineligible for myeloablative hematopoietic cell transplantation (HCT). The aim of this study was to detect
prognostic factors foroverall survival (OS) and to evaluate quality of life (QOL) in a large homogeneous cohort
of 160 consecutive patients aged$60 years treated with allogeneic HCT.We evaluated age, sex, performance
status, comorbidities, pulmonary function, lactic dehydrogenase concentration, type of donor, disease status,
CD341 cells transplanted, cytomegalovirus status, time from diagnosis to HCT, and the development of acute
and chronic graft-versus-host disease (GVHD). All patients who survived for$6 months (n5 79) were asked
to complete a QOL survey. All patients (median age, 64.7 years; range, 60.1-76 years) received pretransplan-
tation conditioning with fludarabine, BCNU, andmelphalan.With a median follow-up of 35months, the 1-year
OSwas 62.4% and3-yearOSwas 47.4%.Multivariate analysis revealed compromised performance status as the
most significant negative prognostic parameter for OS (P\.003), whereas male donor (P5 .008) and chronic
GVHD (P5.024)were associatedwith betterOS. The 89%of survivors who returned theQOL questionnaire
rated their global QOL as good-to-excellent despite impaired functional capabilities and such symptoms as
fatigue, dyspnea, and loss of appetite. The main prognostic factor was performance status, not age. Our data
suggest that toxicity-reduced conditioning offers a chance for enhanced OS with an adequate QOL.
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Hematopoietic cell transplantation (HCT) in
elderly persons remains controversial, primarily be-
cause of its assumed applicability to a small minority
of affected patients, as well as the fear of high
treatment-related mortality and poor overall outcome
[1]. Because age is considered the key risk factor, there1Department of Hematology/Oncology, Albert-Ludwigs
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6/j.bbmt.2010.02.004are limited data on other prognostic parameters and
quality-of-life (QOL) outcomes in older patients
undergoing this procedure; however, patients aged
.60 years are at greatest need of such intensive treat-
ment [2], and issues related to QOL are among the
most serious concerns in cancer survivors [3]. Despite
advances in reducing nonrelapse mortality (NRM)
through reduced-intensity conditioning (RIC) before
transplantation [4], data on NRM vary widely, and
toxicity remains a major concern. Supportive measures
for anticipating individual treatment tolerability and
treatment-related complications are highly desirable
[5]. Along with disease-specific parameters, such as
remission status and cytogenetics [6,7], patient- and
age-specific factors are now being increasingly
considered [8-13].
Our previous experience has demonstrated that
elderly patients and patients with comorbidities can
be successfully treated using a RIC regimen compris-
ing fludarabine, BCNU, and melphalan (FBM)
[14,15]. Here we present a systematic overview of
readily available patient- and disease-specific967
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years, along with a cross-sectional QOL survey of
the survivors, which together compose the largest
data set yet reported on homogeneously treated elderly
HCT patients.METHODS
Patients
All 160 patients were aged$60 years at the time of
transplantation and thus ineligible for conventional
myeloablative (MA) conditioning; all were assigned
to the FBMRIC protocol, described in detail later. Be-
cause 45 of our patients had previously participated in
a 2-center prospective, nonrandomized, opened-label,
phase II clinical trial [15], patient characteristics and
survival data were evaluated in that context.
During the latest outpatient follow-up visit,
survivors of the cohort (n 5 79) were asked to provide
a self-ratedQOLassessment according to theEuropean
Organization for the Recognition and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire. The local
Ethics Committee approved the study design, and all
patients provided informed consent.
Performance Status and Comorbidity
Data from medical records were extracted to iden-
tify each patient’s pretransplantation Karnofsky Index
(KI) performance status and comorbidities docu-
mented by the treating physician at the time of hospital
admission forHCT. For the KI, each patient was given
a score on a linear scale of 0 (dead) to 100 (normally ac-
tive) summarizing his or her ability to perform daily
activities. The Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) was used to evaluate
comorbidities, as described previously [9]. The
HCT-CI assigns points for 17 common medical con-
ditions relevant in the transplantation setting, yielding
in a total score of 0-29. Suspecting an independently
strong impact, we also documented cytomegalovirus
(CMV) status, serum lactate dehydrogenase (LDH)
concentration, and pulmonary function (ie, forced
expiratory volume in 1 minute [FEV1]).
Conditioning, Transplantation Procedure,
GVHD Prophylaxis, and Toxicity Grading
All patients received the toxicity-reduced FBM
regimen as conditioning chemotherapy [15,16]. The
dosage was modified twice during the study period.
Before 2005, 89 patients received fludarabine (Flu) 5
 30 mg/m2 from days 29 to 25, BCNU 2  150
mg/m2 on days 27 and 26, and melphalan (Mel) 110
mg/m2 on day 24. Between July 2005 and August
2006, 36 patients received Flu 4  30 mg/m2 from
days 28 to 25, BCNU 2  150 mg/m2 on days 27and 26, and Mel 110 mg/m2 on day –4. Since August
2006, 35 patients received Flu 4  30 mg/m2 from
days 27 to 24, BCNU 2  150 mg/m2 on days 27
and 26, and Mel 110 mg/m2 on day 24. Initially,
GVHD prophylaxis consisted of cyclosporine A (CsA)
and methotrexate; the latter was later replaced by
mycophenolate mofetil (MMF). All patients with an
unrelated donor received CsA in addition to MMF
and rabbit anti–T-lymphocyte globulin.
Transplantation of stem cell grafts, supportive
care, antimicrobial prophylaxis and treatment, and
transfusion of blood products were performed accord-
ing to standard good clinical practice procedures [14].
Acute GVHD (aGVHD) was assessed using the
criteria of Przepiorka et al. [17]. Chronic GVHD
(cGVHD) was defined as GVHD occurring 100 days
or more after allogeneic HCT and was graded as
none, limited, or extensive [16,18].
HLA Matching
Patients and their related or unrelated donors were
matched for HLA-A and -B class I loci by serologic
techniques (2 digits) and for HLA-DRB1 and
-DQB1 class II alleles by high-resolutionDNA-typing
techniques (4 digits). Patients received granulocyte
colony-stimulating factor–mobilized, unmanipulated
peripheral blood stem cells (PBSCs) or bone marrow
from matched unrelated and related donors.
Disease-Specific Parameters
Disease-specific risk stratification was performed
as described previously [15]. The low-risk group
included patients with chronic myelogenous leukemia
(CML) in chronic phase, acute myelogenous leukemia
(AML) and acute lymphoblastic leukemia (ALL)
in first remission, and myelodysplastic syndrome
(MDS) with refractory anemia (RA) or RA with ringed
sideroblasts (RARS). The high-risk group comprised
patients with non-Hodgkin lymphoma (NHL);
chronic lymphocytic leukemia (CLL); multiple mye-
loma (MM); CML in accelerated phase or blast crisis;
AML or ALL in second or further remission, partial
remission, or relapse; and MDS with RA with excess
blasts (RAEB I and II). MDS and AML cytogenetics
were documented as described previously [19,20].
QOL Aspects
QOLwas evaluated using the EORTCQLQC 30
version 3.0, which has demonstrated good psychomet-
ric utility in evaluating physical aspects ofQOL and as-
sociated symptomatology [21,22]. The questionnaire
contains 1 subscale for global QOL, 5 functioning
subscales, and 9 symptom subscales, with each
subscale linearly converted to a scale of 0-100.
Published reference data for an age- and sex-matched
average German population were used for comparison
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difficulty of presenting 2 means that differ statistically
butmay not be clinically significant or overly important
from a QOL standpoint is to specify a change of a spe-
cific number of points (eg, $10 or 15; usually 1 stan-
dard error of measurement, or 10% of the scale),
which equates to a clinically important difference be-
tween groups. This suggestion is consistent with what
has been identified as the minimally important differ-
ence (MID), the degree of change in a symptom or as-
pect of functioning that is recognizable and important
to patients [24-26]. In the EORTC QLQ C30
questionnaire, a difference of 5-10 points is
considered small, and a difference of 10-20 points is
considered moderate [27]. Thus, in the present study,
mean results of the cross-sectional patient analysis are
interpreted in comparison to the reference population,
focusing on between-group differences of .10 points.Statistical Methods
Patient data were collected between December
1999 and February 2008. Overall survival (OS) was
calculated as the time from transplantation until death
from any cause, or censored at the time of last contact
with the patient. The Kaplan-Meier method was used
to estimate OS with accompanying 95% confidence
intervals (CIs). Cox proportional hazards regression
analysis of potential prognostic factors for OS for the
patient cohort was performed with available variables.
Univariate calculations were performed first, and vari-
ables with a univariate P\.10 were entered into a mul-
tivariate model, in which a backward-selection strategy
(P \.10) was applied. aGVHD and cGVHD were
considered time-dependent covariates.
Patients who died with no evidence of relapse or
disease progression were considered cases of NRM.
NRMand relapsemortalitywere considered competing
risks, and cumulative incidence rates were calculated to
estimate the respective rates. Associations between
prognostic factors were investigated using continuity-
corrected c2 tests from 2  2 tables. All calculations
were made using SAS version 9 (SAS Institute, Cary,
NC).RESULTS
Patient, Donor, and Transplant Characteristics
Table 1 presents baseline characteristics of the 160
consecutive patients. The study group had a median
age of 64.8 years (range, 60-76 years) and was 55.6%
male. Median donor age was 40 years (range, 19-79
years), and 51.3%of donorsweremale.Themedian do-
nor age was 63 years in cases of matched related trans-
plantation (n 5 51) and 35 years in cases of matched
unrelated donor (MUD) transplantation (n 5 109);thus, donor age was significantly associated with the
type of donor (P \.0001). In contrast, recipient age
was not associated with the type of donor (P 5.92).
Eight patients received a bone marrow graft, and 152
patients received a PBSC graft. The median CD341
cell count in the PBSC grafts was 6.12  106/kg body
weight (range, 1.3-23  106/kg).
The median KI score was 80 (range, 30-100), and
the median HCT-CI score was 2 6 1.7 (range, 0-7).
The most common comorbidities were cardiovascular
disease (68.2%) and diabetes mellitus (12.7%).
Diagnoses included AML (n 5 111), MDS (n 5
24), CML (n 5 3), NHL (n 5 11), CLL (n 5 7), MM
(n 5 2), and MPS (n 5 2). Based on disease status, 18
patients were in the low-risk group and 142 were in
the high-risk group. Cytogenetic data were available
in 106 patients with AML or MDS (78.5%); aberra-
tions were identified in 49 cases (46.2%). Nine patients
died before having completed full hematologic engraft-
ment. Documented best responses to treatment were
141 complete remission (CR), 4 partial response
(PR), and 6 stable disease.OS
At a median follow-up of 35 months, 79 patients
(49.4%) were alive. Median OS was 889 days (95%
CI, 428-1404 days). OS was 62.4% (95% CI, 54.7%-
70.1%) after 1 year, 54.1% (95% CI, 45.9%-62.4%)
after 2 years, and 47.7% (95%CI, 38.5%-56.2%) after
3 years.
Cumulative incidence rates for relapse mortality
were 15.5% after 1 year, 19.8% after 2 years, and
22% after 3 years. Median relapse-free survival was
418 days, or 84.4% at 100 days, 52% at 1 year,
42.6% at 2 years, and 39.2% at 3 years.
Of the 81 patients who died, 36 (44.4%) died of re-
lapse and45 (55.6%)diedofNRM(Figure1).NRMwas
8.1% at 100 days, 22.1% at 1 year, and 30.6% at 3 years.
Fatal infection was the leading cause of death (64.4%),
whereas cardiovascular complications accounted for
15.6% of NRM and cGVHD (n 5 5) accounted for
11% of NRM.Prognostic Factor Analysis
Table 2 summarizes the results of univariate analysis
for risk factors for OS. Multivariate regression analysis
for variables that had a P\.10 in univariate analysis
was performed as illustrated in Table 2. A KI score of
#80 was associated with an elevated hazard ratio (HR)
of 2.01 (95% CI, 1.27-3.18; P 5.0026), with markedly
reduced survival in the entire follow-upperiod, as shown
in Figure 2. For patients with a KI #80, the cause-
specific HR was 2.66 for relapse mortality (P 5.0069)
and 1.61 for NRM (P 5.118). A KI of#70 was associ-
ated with even poorer prognosis (HR, 2.36; 95% CI,
Figure 1. Cumulative incidence: Relapse mortality versus NRM.
Table 1. Characteristics of Patients, Donors, and Grafts
Patient-specific parameters
Age, years, median (range) 64.8 (60.1-76)
Male, n (%) 89 (55.6)
KI score, median (range) 80 (30-100)
HCT-CI, median (range) 2 (0-7)
Disease-specific parameters
Diagnosis, n (%)
CML 3 (1.9)
Chronic phase 1 (0.63)
Blast crisis 1 (0.63)
Accelerated phase 1 (0.63)
MDS 24 (15)
RA 6 (3.7)
RAEB/t, CMMoL 18 (11.2)
AML 111 (69.4)
CR1 11 (6.9)
Relapse/refractory 67 (41.9)
CR2 or greater 6 (3.7)
Untreated 27 (16.8)
MPS/OMF 2 (1.2)
MM (PR) 2 (1.2)
NHL* 11 (6.9)
Primary induction failure 3 (1.9)
Progression after standard treatment 8 (5)
CLL 7 (4.4)
Risk group, n (%)†
High 142 (88.75)
Low 18 (11.25)
Cytogenetics in MDS/AML, n (%) 106 (78.5)
Normal 57 (53.8)
Favorable 4 (3.8)
Intermediate 7 (6.6)
Poor 38 (35.8)
Donors and grafts
Donor age, years, median (range) 40 (19-79)
Related donor, n (%) 51 (31.9)
Age, years, median (range) 63 (35-79)
Unrelated donor, n (%) 109 (68.1)
Age, years, median (range) 35 (19-66)
Sex match, n (%)
Patient male/donor female 41 (25.62)
Patient female/donor male 34 (21.25)
Patient female/donor female 37 (23.13)
Male patient/male donor 48 (30.0)
Graft source, n (%)
Bone marrow stem cells 8 (5)
Peripheral blood stem cells 152 (95)
CD34+ cell count, median (range)‡ 6.12  106/kg (1.3-23  106/kg)
CMV status, n (%)
Recipient-positive 112 (70)
Donor-positive 81 (50.6)
GVHD, n (%)
aGVHD
None 82 (51.2)
Grade I 34 (21.2)
Grade II 21 (13.1)
Grade III 17 (10.6)
Grade IV 6 (3.7)
cGVHD
None 71 (44.4)
Limited 35 (21.9)
Extensive 35 (21.9)
HCT-CI indicates Hematopoietic Cell Transplantation Comorbidity In-
dex; KI, Karnofsky Index; CML, chronic myelogenous leukemia; MDS,
myelodysplastic syndrome; RA, refractory anemia; RAEB, refractory
anemia with excess blasts; AML, acute myelogenous leukemia; CR1, first
complete remission; CR2, second complete remission; MM, multiple
myeloma; NHL, non-hodgkin lymphoma; GVHD, graft-versus-host dis-
ease; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease.
*NHL diagnoses included follicular lymphoma (n 5 3), mantle cell
lymphoma (n 5 5), diffuse large cell lymphoma (n 5 2), and T cell
lymphoma (n 5 1) .
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patients, however (n5 33).
Half of the donorsweremale (with a slight predom-
inance of male donors in MUD HCT [60:49] and of
female donors in related HCT [29:22]). Female donor
was identified as an adverse factor for OS (HR, 1.82;
P 5.0085). The negative impact was similar in the 41
male recipients and the 37 female recipients, with
respective mortality rates of 56.1% and 56.8%. Female
recipient was associated with an HR of 1.32 (P 5 not
significant). No associations between donor sex and
recipient age (P 5.88), donor age (P 5.09), cGVHD
(P 5 1.0), or type of donor (P 5.21) were apparent;
however, female donor was significantly associated
with a CD341 cell count below the median level of
6.12  106/kg of body weight (P \.0001). Female
recipient was associated with poorer respiratory
function (P\.0001) and a highermedian number of co-
morbidity factors (P 5.06), but not with significantly
poorer general performance status (P5.64).
aGVHD (defined as GVHD occurring before 100
days posttransplantation) was evident in 78 patients
(grade I-II, 34.3%; grade III-IV, 14.3%) and was not
associated with any significant decrease or increase in
HR. Limited and extensive cGVHD were evaluable
in 70 patients and were associated with a significantly
reduced risk of death (HR, 0.52), because of a de-
creased rate of relapse mortality. Only 11% of patients
with cGVHD died of relapse, as opposed to 31% of 71
patients without cGVHD.
Neither CD341 cell count nor type of donor had
a statistically significant association with cGVHD
(P 5.862 and .789, respectively). Transplantation of†Two risk groups were defined. The low-risk group included CML in
chronic phase, AML and ALL in first remission, and MDS-RA/RARS
(n5 18). The high-risk group included NHL; MM; CLL; CML in acceler-
ated phase or blast crisis; AML or ALL in CR2 or further remission, PR,
or relapse; and MDS RAEB (n 5 142).
‡Peripheral blood HCTonly.
Table 2. Risk Factors for OS after HCT
Variable Incidence, n (%) HR 95% CI P
Univariate Cox regression analysis (n 5 160)
KI #80 82 (51.2) 1.99 1.27-3.14 .0028
cGVHD (all grades)* 70 (43.8) 0.51 0.29-0.88 .0165
Patient age $65 years 76 (47.5) 0.58 0.37-0.93 .0229
Female donor 78 (48.7) 1.60 1.03-2.49 .0350
Female recipient 71 (44) 1.52 0.98-2.35 .0618
CD34+ <6  10E6† 80 (59) 1.53 0.98-2.36 .0619
HCT-CI $2 94 (58.7) 1.37 0.87-2.15 .1679
FEV1 <80 49 (30.6) 1.38 0.86-2.20 .1777
MUD 109 (68.1) 0.74 0.46-1.17 .1955
Extensive cGVHD 35 (21.9) 0.73 0.38-1.38 .3336
Donor age $40 years 79 (49.4) 1.18 0.75-1.86 .4732
High-risk disease status 142 (88.7) 1.32 0.60-2.86 .4829
HCT >1 year after initial diagnosis 46 (28.7) 1.16 0.73-1.86 .5256
CMV+ donor 81 (50.6) 1.20 0.77-1.86 .6637
CMV+ recipient 112 (70) 1.11 0.69-1.79 .6637
aGVHD (all grades)* 77 (48.1) 0.93 0.59-1.47 .7672
Median serum lactate dehydrogenase $215 IU/L 95 (59.37) 1.05 0.67-1.64 .8210
Adverse cytogenetics‡ 38 (35.8) 1.06 0.62-1.81 .8298
Multivariate Cox regression analysis§ of pretransplantation factors for outcome,
all patients (n 5 160)
KI #80 2.01 1.27-3.18 .0026
Female donor 1.83 1.17-2.86 .0085
cGVHD* 0.52 0.29-0.92 .0235
Patient age $65 years 0.60 0.38-0.95 .0311
Multivariate Cox regression analysis§ of pretransplantation factors for outcome,
MDS/AML patients only (n 5 135)
KI #80 1.94 1.17-3.19 .0097
Female donor 1.67 1.02-2.74 .0403
cGVHD* 0.60 0.33-1.09 .0976
Patient age $65 years 0.57 0.35-0.95 .0323
HCT-CI indicates Hematopoietic Cell Transplantation Comorbidity Index; KI, Karnofsky Index; CML, chronic myelogenous leukemia; MDS, myelodys-
plastic syndrome; AML, acute myelogenous leukemia; CMV, cytomegalovirus; FEV1, forced expiratory volume in 1 minute; GVHD, graft-versus-host
disease; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; MUD, matched unrelated donor.
*Time-dependent.
†Peripheral blood HCTonly.
‡MDS/AML only.
§Factors considered for backward selection were P <.10 in univariate analysis.
Figure 2. Survival distribution according to the KI. Good pretransplan-
tation performance retains relevance in the protracted clinical course.
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kg) in peripheral blood HCT was associated with an
increasedHR of survival (1.52; P5.06, univariate anal-
ysis). Donor age above the median of 40 years did not
increase HR significantly. Forty-six patients under-
went transplantation more than 1 year after initial di-
agnosis; delayed HCT was not associated with
a significant increase in HR.
Concomitant diseases according to the HCT-CI
were documented as follows: 34 patients (21.3%) had
no relevant comorbidity, whereas 32 patients (14%)
had a score of 1, 34 patients (21.3%) had a score of
2 points, and 60 patients (37.5%) had a score of $3
points. The categorization of patients with an HCT-
CI score of$2 did not reach significance in univariate
analysis (HR, 1.37; P 5.17).
TheHRs associated with disease-specific high-risk
groups or poor-risk cytogenetics (in AML patients) did
not reach significance; however, high-risk disease
(present in 142 patients) was significantly associated
with a lower performance status (P 5.002). Patient
age $65 years was associated with an HR decrease of0.6, and was not associated with any negative prognos-
tic factors (eg, poor performance status, female sex,
absence of cGVHD).
Table 3. EORTC QLQ C30: Comparison of Results of Survivors with the German Reference Population after a Median of 22.5
Months Posttransplantation
Patients (Median Age, 69 Years) Reference German Population (Age 60-69 Years) [23]
Total (n 5 70) Male (n 5 45) Female (n 5 25) Male (n 5 193) Female (n 5 197)
Functional scales
Physical functioning 72.9 78.7 63.5 86.5 83.8
Role functioning 64.4 68.2 58.3 84.5 82.1
Emotional functioning 72.6 74.8 68.7 80.5 75.9
Cognitive functioning 77.8 77.3 78.5 88.3 88.7
Social functioning 64.2 67.8 59.0 86.7 90.9
Global QOL 65.7 67.8 62.5 65.6 62.6
Symptom scales
Fatigue 38.7 34.4 45.8 18.6 23.0
Nausea/vomiting 4.9 2.6 10.4 2.2 2.8
Pain 24.4 18.9 33.3 20.3 23.9
Dyspnea 25.6 23.7 28.0 12.6 11.7
Insomnia 29.4 21.5 43.0 19.5 29.8
Appetite loss 19.3 12.6.7 32 6.2 6.6
Constipation 9.4 4.4 20.3 3.5 6.3
Diarrhea 19.6 14.8 27.8 2.1 2.2
For the functional and global QOL scores, a higher score presents a better functioning level. For the symptom scales and items, a higher score reflects
more symptoms. A clinically relevant difference of$10 points between patients and reference population is apparent in the domains of role and social
functioning, fatigue, insomnia, dyspnea, appetite loss, and diarrhea.
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peated for the largest subgroup of 135 patients with
MDS/AML yielded results similar to those for all
patients (Table 2).QOL Aspects and Follow-Up
The 79 survivors were asked to complete the QLQ
C30 questionnaire at last contact after a median of 22.5
months (range, 6-98 months); 70 (89%; 64.3% male)
complied. The patients reported several symptoms,
andmosthaddecreased functional levels, yet impairment
of global QOLwas minimal. A comparison of the entire
cohort to the published sex-matched German reference
data (age cohort 60-69 years), summarized in Table 3,
yielded similar values, with cutoff scores of 10 points dif-
ference indicating the MID [25]. In the subgroup of 32
patients aged$ 70 years at the time of the survey, global
QOL values were higher than the reference values (74 vs
55 for females and 68 vs 61.5 for males). Patient
impairmentwasmostobvious in role and social function-
ing. The most prevalent symptoms were fatigue, pain,
dyspnea, insomnia, and loss of appetite, with female
patients persistently demonstrating greater impairment
and more symptoms.
Only minimal differences in posttransplantation
patient-rated global QOL values based on pretrans-
plantation disease status or the occurrence of cGVHD
were detected. However, a tendency toward improved
globalQOLvalues was seen in patients with a pretrans-
plantation HCT-CI of\2 versus those with an HCT-
CI of $2 (68.8 vs 61.6) and in those with an unrelated
donor (68.3 vs 59.6). At last contact with the 79 survi-
vors, 30 (38%) had a KI of 100, 32 (40.5%) had a KI of
90, 12 (15.2%) had a KI of 80, and 5 (6.3%) had a KI of70, indicating that all were able to live an independent
life and few being compromised in daily activities.DISCUSSION
The present evaluation of patient data after FBM
conditioning and allogeneic HCT has focused on pa-
tients aged .60 years, because advanced age is postu-
lated to be a major risk factor for intensive
chemotherapeutic treatment [28,29]. The previously
reported poor survival data in elderly patients with
hematologic malignancies underscore the need to
improve treatment options, particularly because
.50% of these patients are considered unfit for
intensive chemotherapeutic treatment [30]. The advent
of RIC regimens has led to reduced toxicity and NRM
[31,32].
In MA HCT, postulated risk factors include age,
disease stage, cytogenetics, and pretransplantation se-
rum ferritin concentration [13], as well as unrelated
donor, high disease risk, impaired organ function
[33], disease duration, donor sex, and HLA disparity
[34] as predictors of NRM. We have found that
FBM conditioning leads to high CR rates with accept-
able toxicity in older patients and encouraging long-
term effectiveness even in advanced disease [15]. Our
evaluation of prognostic factors has revealed that older
age does not necessarily translate into poorer outcome.
In our patient cohort, NRM was 8% after 100 days,
22% after 1 year, and 31% after 3 years, demonstrating
the feasibility or our approach. Others have published
similar data in smaller trials using low-dose total body
irradiation (2Gy) and Flu in patients with amedian age
of 60-64 years [35-37]. Several trials that included
Biol Blood Marrow Transplant 16:967-975, 2010 973Risk Factors and Quality of Life in Elderly HCT Patientsyounger patients reported similar outcomes
[11,38,39].
An age limitation has been suggested to be more
important in unrelated donor transplantations than
in sibling donor transplantations [40]. However, like
others before us [4,41,42], we found no significant
difference in risk between the 2 modalities. Recent
data suggest that younger donor age is beneficial for
outcome in patients receiving an RIC regimen [43].
In our study group, the unrelated donors were much
younger than the sibling donors (Table 1), which
might be one reason (even though it was not a signifi-
cant parameter) why patients with an MUD fared no
worse than the other patients.
Female sex of both recipient and (especially) donor
was disadvantageous. Statistical calculations revealed
no significant associations among female sex and other
risk factors found to be relevant in our cohort. This
finding is probably because of a combined effect of
a lower transfused CD341 cell dose (a factor some be-
lieve to be adverse [44]), impaired organ function (eg,
lower FEV1, higher HCT-CI), and perhaps reduced
compensation strategies in our female patients. The
latter may be implied by the lower QOL values in
eg, role and social functioning and higher scores in
most of the QOL symptom scales in elderly females
compared with their male counterparts (Table 3). No
data on smoking habits or other possible causes of pul-
monary damage were available, precluding analysis of
the poorer respiratory function seen in female patients.
The small number of patients, the large number of
prognostic factors studied, and the RIC regimenmight
explain why some previously proposed risk factors
were not significant in our study. Screening of larger
cohorts is needed to verify our findings.
Patientswhodeveloped cGVHDhad anOSbenefit
because of a decreased rate of relapse mortality, in
agreement with a previous study [45]. This benefit
was retained to a small degree even for extensive man-
ifestations.
The HCT-CI is a recently defined patient-specific
parameter. Although some authors consider theHCT-
CI a significant predictor of posttransplantation NRM
and OS [9,46], our data and those of others do not
support this finding [47-49]. Notably, our patients’
individual KIs were highly significant in predicting
survival outcome. As shown in Figure 2, good pre-
transplantation performance status retained its posi-
tive impact throughout the follow-up period.
Interestingly, analysis of cumulative mortality inci-
dence in patients with reduced performance status
revealed an increased HR, especially for relapse mor-
tality. The most likely explanation for this finding is
the significant association between poor performance
and high-risk disease, and thus an increased risk of
relapse. Because clinicians may tend to focus on the
burden of malignancy rather than on other medicalconditions when assigning performance status scores,
these performance status scales may be of only limited
value in identifying risks for NRM. We found that
HCT-CI and performance status were independent
of one another, in agreement with this assumption
and other published findings [50]. Further studies
that prospectively examine parameters so as to better
define ‘‘performance status,’’ as well as enhance its
role in the clinical prediction of tolerability, NRM,
and OS, are needed. Such trials may need to include
parameters of a comprehensive geriatric assessment,
such as in-depth measurement of functional abilities
and independence [51].
Selection bias must be discussed when comparing
our data with previously published results. The charac-
teristics of our patients were comparable to the high-
risk features of other RIC populations [15,38,43,46,52].
Because most of the patients referred to our unit
underwent HCT as soon as a suitable donor was
identified, selection processes might have been applied
at earlier stages. Further work must focus on
parameters considered to represent exclusion criteria
for the presentation of a patient in a transplantation
center.
TheconsiderationofQOLis especially important in
counseling, treatment, and posttreatment management
of intensive therapies such as HCT [53]. These QOL
data are the first to describe a large cohort of elderly pa-
tients who underwent RIC HCT. Our cross-sectional
analysis has several shortcomings, because it can give
only an impression of the posttransplantation QOL in
long-term survivors. It must be followed by prospective
investigations that also document individual dynamic
QOL developments and acknowledge attrition.
Generally, our patients evaluated their global
QOL as good and nearly equal to that in the German
reference data (Table 3) [23]. Because the majority of
patients were more than 1 year beyond transplanta-
tion, the good overall data may be a result of improved
QOL during early recovery. As others have described,
2-year survivors report a return to baseline or better
QOL by day 100 [54]. Even the presence of cGVHD
did not diminish the subjective estimation of global
QOL in our patients. Whereas patients reported sev-
eral symptoms (especially fatigue, dyspnea, insomnia,
and appetite loss), and most did not achieve functional
levels quite as high as their average population coun-
terparts, most judged their global QOL impairment
to be minor. Further subgroup analyses (eg, patients
age $70 years; n 5 32) revealed that with increasing
age, posttransplantation global QOL was even better
than that in the average population. Moreover, com-
pared with a much younger post–MA transplantation
population (mean age: 45 years; n5 34), the variations
in results did not demonstrate a relevant 10-point dif-
ference and were similarly satisfying [25,55]. In this
context, the study of Lee et al. [56] and several older
974 Biol Blood Marrow Transplant 16:967-975, 2010B. Deschler et al.QOL studies found that although certain distressing
symptoms persisted, overall QOL and global measures
of recovery at 6, 12, and 24 months were quite good in
MA conditioning settings. As reported by Neitzert
et al. [57], survival is associated with a high global
QOL score; nevertheless, recovery from HCT is ac-
companied by a number of psychosocial difficulties.
One reason for the positive interpretation of global
QOL might be cognitive reappraisal as a response to
a life-threatening disease [58]. Future investigations
will need to develop therapeutic models that help elim-
inate debilitating symptoms.
Our aim in the present study was to highlight
patient-specific factors that might be relevant to deter-
mining prognoses and in decision making processes. It
is our experience that RIC HCT in patients aged $60
years, even those with advanced and high-risk hemato-
logic diseases, is feasible and offers a chance for
long-term survival and cure. Good performance status
outweighs age as a prognostic marker. Importantly,
surviving patients judge their QOL to be good to
excellent despite some limitations in functional
abilities and certain impairments.ACKNOWLEDGMENTS
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